Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, DNA Virus Infections, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Papillomavirus Infections

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase 1/2 Active not recruiting

296 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT04180215 2025-09-15

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Phase 1/2 Completed

198 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Neoplasms, Squamous Cell

NCT06771674 2025-09-09

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Completed

662 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT03336606 2025-07-10

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Phase 1 Active not recruiting

35 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Squamous Cell

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1 Completed

58 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Neoplasms, Squamous Cell

NCT04357873 2025-02-19

PEVOsq

Phase 2 Completed

112 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT00542308 2023-08-03

Zalutumumab in Non-curable Patients With SCCHN

Phase 2 Completed

90 enrolled 10 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03634982 2022-09-01

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1 Unknown

133 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Noonan Syndrome, Ovarian Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Neoplasms, Squamous Cell

NCT04435938 2020-12-02

SHINE

Phase 2 Unknown

38 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00011492 2020-11-27

Patient Evaluation for Head and Neck Surgery Branch Studies

Terminated

62 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Pharyngeal Neoplasms, Neoplasms, Squamous Cell

NCT01111058 2020-04-07

Everolimus Versus Placebo in Head and Neck Cancer

Phase 2 Terminated

52 enrolled 13 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01581970 2019-09-11

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Phase 2 Completed

7 enrolled 9 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01016769 2019-06-26

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Phase 1/2 Completed

48 enrolled 15 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00661427 2018-01-11

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2 Completed

61 enrolled 8 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01721525 2017-10-25

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Phase 1 Completed

10 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00591149 2017-06-14

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Phase 2 Terminated

16 enrolled 5 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT00272181 2015-12-23

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Phase 2 Terminated

15 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT00412776 2015-12-23

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Phase 2/3 Terminated

165 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT01075828 2014-08-29

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Completed

221 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01075841 2014-07-02

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Withdrawn

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01358097 2014-04-10

Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy

Completed

33 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Neoplasms, Squamous Cell

NCT00382031 2013-10-15

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Phase 3 Completed

286 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01283906 2013-09-12

MuGard

Phase 4 Completed

120 enrolled

Head & NeckOther

Head and Neck Neoplasms, Stomatitis, Neoplasms, Squamous Cell, Mucositis

NCT00485485 2012-08-07

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Phase 2 Completed

7 enrolled 7 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00363441 2012-01-19

A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck

Phase 2/3 Withdrawn

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00401401 2011-12-23

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Phase 1/2 Terminated

30 enrolled 13 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00507858 2011-09-23

Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer

Phase 1 Completed

36 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00229723 2009-08-04

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

224 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT00255476 2009-04-23

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Phase 2 Completed

64 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

VERSATILE-003

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

QoLATI

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

PEVOsq

Zalutumumab in Non-curable Patients With SCCHN

Safety Study of SEA-CD40 in Cancer Patients

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

SHINE

Patient Evaluation for Head and Neck Surgery Branch Studies

Everolimus Versus Placebo in Head and Neck Cancer

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy

Zalutumumab in Patients With Non-curable Head and Neck Cancer

MuGard

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study